Grand View Capital

SciClone Pharmaceuticals is a specialty pharmaceutical company engaged in the development and commercialization of therapies primarily for oncology, infectious diseases, and cardiovascular disorders. Headquartered in Foster City, California, the company’s lead product, ZADAXIN, is utilized for treating hepatitis B and C, certain cancers, and as an immune system enhancer, with ongoing development aimed at addressing sepsis. In addition to ZADAXIN, SciClone markets various products, including DC Bead, which is approved for liver cancer treatment in multiple countries, and ondansetron RapidFilm for managing nausea and vomiting related to cancer therapies. The company has established strategic partnerships to promote products like Angiomax and Cleviprex. With a focus on addressing unmet medical needs, particularly in the rapidly growing markets of China, SciClone Pharmaceuticals continues to expand its portfolio and enhance its global presence.

Menusifu, founded in 2013 and based in the United States, is a data-driven company focused on transforming restaurant management through advanced technology. It offers a comprehensive operation management system that enhances various aspects of restaurant operations, including supply chain management, customer relations, and staff scheduling. The platform serves as a point-of-sale system that not only streamlines ordering processes but also collects and analyzes customer transaction data, providing insights through user-friendly reports and graphs. Menusifu aims to simplify restaurant management, enabling operators to improve efficiency and productivity as it expands its presence in North America.